BACKGROUND: The majority of patients with breast carcinoma receive chemotherapy as a component of multimodality treatment. Over the past decade, it has become increasingly more common to deliver chemotherapy first, but this has raised new questions within all disciplines of cancer management. METHODS: The authors reviewed published studies on the effect of neoadjuvant chemotherapy for breast carcinoma on the practice of medical oncology, surgical oncology, radiation oncology, pathology, and radiology. RESULTS: Treating breast carcinoma with neoadjuvant chemotherapy has several advantages, such as providing the earliest possible treatment against preexisting micrometastases, offering selected patients breast conservation therapy, and allowing for measurement of disease response, which can then be used to customize subsequent chemotherapy. However, neoadjuvant chemotherapy affects the practice not only of medical oncology, but also has important implications for the specialties of surgery, radiology, pathology, and radiation oncology. The current review addressed the new opportunities and challenges within the multidisciplinary care of breast carcinoma provided by neoadjuvant chemotherapy. CONCLUSIONS: The complexity of the issues led the authors to conclude that patients who receive neoadjuvant chemotherapy are likely to benefit from a coordinated multidisciplinary approach to their care. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11603
BACKGROUND: The majority of patients with breast carcinoma receive chemotherapy as a component of multimodality treatment. Over the past decade, it has become increasingly more common to deliver chemotherapy first, but this has raised new questions within all disciplines of cancer management. METHODS: The authors reviewed published studies on the effect of neoadjuvant chemotherapy for breast carcinoma on the practice of medical oncology, surgical oncology, radiation oncology, pathology, and radiology. RESULTS: Treating breast carcinoma with neoadjuvant chemotherapy has several advantages, such as providing the earliest possible treatment against preexisting micrometastases, offering selected patients breast conservation therapy, and allowing for measurement of disease response, which can then be used to customize subsequent chemotherapy. However, neoadjuvant chemotherapy affects the practice not only of medical oncology, but also has important implications for the specialties of surgery, radiology, pathology, and radiation oncology. The current review addressed the new opportunities and challenges within the multidisciplinary care of breast carcinoma provided by neoadjuvant chemotherapy. CONCLUSIONS: The complexity of the issues led the authors to conclude that patients who receive neoadjuvant chemotherapy are likely to benefit from a coordinated multidisciplinary approach to their care. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11603
Authors: C Abrial; M A Mouret-Reynier; S Amat; I Sillet-Bach; P Bougnoux; R Delva; H Cure; J Dauplat; F Penault-Llorca; P Chollet Journal: Med Oncol Date: 2005 Impact factor: 3.064
Authors: Aida Kuzucan; Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Philip M Carpenter; Peter T Fwu; Hon J Yu; David J B Hsiang; Karen T Lane; John A Butler; Stephen A Feig; Min-Ying Su Journal: Clin Breast Cancer Date: 2012-04 Impact factor: 3.225
Authors: Lisa König; Sabine Kasimir-Bauer; Ann-Kathrin Bittner; Oliver Hoffmann; Bettina Wagner; Luis Felipe Santos Manvailer; Rainer Kimmig; Peter A Horn; Vera Rebmann Journal: Oncoimmunology Date: 2017-09-27 Impact factor: 8.110
Authors: Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Aida Kuzucan; Hon J Yu; Philip M Carpenter; Stephen A Feig; Muqing Lin; David J B Hsiang; Karen T Lane; John A Butler; Orhan Nalcioglu; Min-Ying Su Journal: Radiology Date: 2011-08-30 Impact factor: 11.105
Authors: Hiroaki Kurihara; David J Yang; Massimo Cristofanilli; William D Erwin; Dong-Fang Yu; Saady Kohanim; Richard Mendez; E Edmund Kim Journal: Appl Radiat Isot Date: 2008-01-26 Impact factor: 1.513